STRO
SUTRO BIOPHARMA, INC.
$28.80
+8.76%
$477.2M
No data for this timeframe.
Vol
Market Cap$477.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders35 funds
Inst. Value$111.5M
Inst. Activity8 buys / 2 sells
SEC Reports2
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001382101·Prev Close $26.48
Recent Activity
Jun 5, 2026
Insider
Wigginton Jon Marc was granted 10,000 shares
Director
Jun 5, 2026
Insider
Petree Daniel H was granted 10,000 shares
Director
Jun 5, 2026
Insider
PANEK JAMES P was granted 10,000 shares
Director
May 14, 2026
earnings
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
<p align="center"><em>– On track to report initial safety, PK and early activity from</em> <em>Phase
Apr 22, 2026
SEC
Sutro Biopharma is holding its annual shareholder meeting to elect directors, ratify auditors, and approve executive com
DEFA14A — Impact 3/10
Mar 23, 2026
SEC
Sutro Biopharma has filed an S-3 shelf registration allowing it to raise up to $300 million in various securities, inclu
S-3 — Impact 6/10
Inst.
RA CAPITAL MANAGEMENT, L.P. — NEW
715,307 shares ($17.8M)
Inst.
Point72 Asset Management, L.P. — DOUBLED
692,111 shares ($17.2M)
Price Targets
$48.31
+67.7% upside
Strong Buy
Current $28.80
Low $10.00
Median $50.00
High $61.00
13 analysts
$10.00
$61.00
Analyst Ratings
5Strong Buy
13Buy
1Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Barclays | INITIATE | Overweight |
| May 15, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| May 15, 2026 | Wedbush | UPGRADE | Neutral → Outperform |
| May 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 30, 2026 | Mizuho | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.39 | $-2.63 — $-2.12 | -71% YoY | 3 |
| Next Q | $-2.46 | $-2.86 — $-2.10 | 56% YoY | 3 |
| Current FY | $-7.80 ▼ -16.3% | $-8.31 — $-7.30 | 52% YoY | 2 |
| Next FY | $-6.88 ▼ -177.6% | $-10.31 — $-4.86 | 12% YoY | 4 |
Latest Reports
NEUTRAL
DEFA14A
3/10
Sutro Biopharma is holding its annual shareholder meeting to elect directors, ratify auditors, and approve executive com
Apr 22, 2026
BULLISH
Press
7/10
Sutro Biopharma presented promising preclinical data for its next-generation antibody-drug conjugates (ADCs), including
Apr 19, 2026
BEARISH
S-3
6/10
Sutro Biopharma has filed an S-3 shelf registration allowing it to raise up to $300 million in various securities, inclu
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $17.9M | — |
| RA CAPITAL MANAGEMENT, L.P. | $17.8M | NEW |
| Point72 Asset Management, L.P. | $17.2M | DOUBLED |
| BALYASNY ASSET MANAGEMENT L.P. | $11.6M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Wigginton Jon | A | $0.00 |
| Jun 5, 2026 | Petree Daniel | A | $0.00 |
| Jun 5, 2026 | PANEK JAMES | A | $0.00 |
| Jun 5, 2026 | Lobacki Joseph | A | $0.00 |
| Jun 5, 2026 | Jagpal Sukhi | A | $0.00 |
35 institutional holders with $111.5M total value (4,476,858 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, RA. Net buying activity: 8 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 12 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 720,442 | $17.9M | 16.1% | — |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 715,307 | $17.8M | 16.0% | NEW |
| 4 | Point72 Asset Management, L.P. | 692,111 | $17.2M | 15.5% | DOUBLED +286.5% |
| 5 | BALYASNY ASSET MANAGEMENT L.P. | 465,792 | $11.6M | 10.4% | DOUBLED +102.5% |
| 6 | Woodline Partners LP | 457,441 | $11.4M | 10.2% | NEW |
| 7 | BlackRock, Inc. | 232,684 | $5.8M | 5.2% | ADD +98.1% |
| 8 | MARSHALL WACE, LLP | 222,634 | $5.5M | 5.0% | DOUBLED +160.0% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 200,000 | $5.0M | 4.5% | — |
| 10 | CITADEL ADVISORS LLC | 117,537 | $2.9M | 2.6% | — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 97,824 | $2.4M | 2.2% | — |
| 12 | VANGUARD FIDUCIARY TRUST CO | 94,838 | $2.4M | 2.1% | — |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 84,902 | $2.1M | 1.9% | — |
| 14 | TWO SIGMA INVESTMENTS, LP | 65,176 | $1.6M | 1.5% | — |
| 15 | STATE STREET CORP | 52,118 | $1.3M | 1.2% | ADD +52.1% |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 36,600 | $911.7K | 0.8% | — |
| 17 | Trexquant Investment LP | 34,343 | $855.5K | 0.8% | — |
| 18 | GOLDMAN SACHS GROUP INC | 27,187 | $677.2K | 0.6% | — |
| 19 | CITADEL ADVISORS LLC | 24,800 | $617.8K | 0.6% | — |
| 20 | BANK OF AMERICA CORP /DE/ | 18,873 | $470.1K | 0.4% | DOUBLED +348.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 715,307 | — | $17.8M | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 179,088 | 692,111 | +286.5% | $17.2M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 230,049 | 465,792 | +102.5% | $11.6M | 2026-Q1 |
| Woodline Partners LP | NEW | — | 457,441 | — | $11.4M | 2026-Q1 |
| BlackRock, Inc. | ADD | 117,437 | 232,684 | +98.1% | $5.8M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 85,615 | 222,634 | +160.0% | $5.5M | 2026-Q1 |
| STATE STREET CORP | ADD | 34,266 | 52,118 | +52.1% | $1.3M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4,212 | 18,873 | +348.1% | $470.1K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 15,922 | 10,529 | -33.9% | $262.3K | 2026-Q1 |
| CWM, LLC | TRIM | 1,499 | 983 | -34.4% | $24.5K | 2026-Q1 |
12 unique insiders with 25 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Wigginton Jon Marc | Director | AWARD | 10,000 | — | — |
| Jun 5, 2026 | Petree Daniel H | Director | AWARD | 10,000 | — | — |
| Jun 5, 2026 | PANEK JAMES P | Director | AWARD | 10,000 | — | — |
| Jun 5, 2026 | Lobacki Joseph M | Director | AWARD | 10,000 | — | — |
| Jun 5, 2026 | Jagpal Sukhi | Director | AWARD | 10,000 | — | — |
| Jun 5, 2026 | Hunter Heidi | Director | AWARD | 10,000 | — | — |
| Jun 5, 2026 | Dybbs Michael | Director | AWARD | 10,000 | — | — |
| Jun 5, 2026 | MATSUI CONNIE | Director | AWARD | 10,000 | — | — |
| Jun 2, 2026 | Chow Gregory K. | CFO | EXERCISE | 2,500 | — | — |
| Mar 4, 2026 | Pauling David | Chief Admin. Ofcr. & GC | EXERCISE | 675 | — | — |
| Mar 4, 2026 | Chung Jane | Chief Executive Officer | EXERCISE | 788 | — | — |
| Mar 2, 2026 | Chow Gregory K. | CFO | AWARD | 40,000 | — | — |
| Mar 2, 2026 | Chow Gregory K. | CFO | AWARD | 5,000 | — | — |
| Mar 2, 2026 | Pauling David | Chief Admin. Ofcr. & GC | EXERCISE | 2,356 | — | — |
| Mar 2, 2026 | Pauling David | Chief Admin. Ofcr. & GC | AWARD | 4,200 | — | — |
| Mar 2, 2026 | Pauling David | Chief Admin. Ofcr. & GC | AWARD | 33,600 | — | — |
| Mar 2, 2026 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | EXERCISE | 2,843 | — | — |
| Mar 2, 2026 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | AWARD | 5,000 | — | — |
| Mar 2, 2026 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | AWARD | 40,000 | — | — |
| Mar 2, 2026 | Chung Jane | Chief Executive Officer | EXERCISE | 7,750 | — | — |
| Mar 2, 2026 | Chung Jane | Chief Executive Officer | AWARD | 40,000 | — | — |
| Mar 2, 2026 | Chung Jane | Chief Executive Officer | AWARD | 175,000 | — | — |
| Mar 1, 2026 | Pauling David | Chief Admin. Ofcr. & GC | EXERCISE | 500 | — | — |
| Mar 1, 2026 | Chung Jane | Chief Executive Officer | EXERCISE | 688 | — | — |
| Mar 1, 2026 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | EXERCISE | 1,125 | — | — |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 4.5/10.
Current analyst consensus: Strong Buy (90% buy). Based on 20 analysts: 5 strong buy, 13 buy, 1 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$48.31 mean target
+67.7% upside
Strong Buy (1.38)
$10.00 Low
$61.00 High
| Metric | Value |
|---|---|
| Current Price | $28.80 |
| Target Low | $10.00 |
| Target Mean | $48.31 |
| Target Median | $50.00 |
| Target High | $61.00 |
| # Analysts | 13 |
| Recommendation | Strong Buy (1.38) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.39 | $-2.63 | $-2.12 | -70.8% | — | — | $0.0B | -83.2% | 3 |
| Next Q 2026-09-30 |
$-2.46 | $-2.86 | $-2.10 | 55.9% | — | — | $0.0B | -9.5% | 3 |
| Current FY 2026-12-31 |
$-7.80 | $-8.31 | $-7.30 | 51.8% | -16.3% | 0↑ 1↓ | $0.0B | -56.0% | 2 |
| Next FY 2027-12-31 |
$-6.88 | $-10.31 | $-4.86 | 11.8% | -177.6% | 0↑ 1↓ | $0.0B | -28.5% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.392 | |
| 7d ago | $-2.420 | +0.028 |
| 30d ago | $0.000 | -2.392 |
| 60d ago | $0.000 | -2.392 |
| 90d ago | $0.000 | -2.392 |
8 analyst firms have rated this stock: 4 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Barclays | INITIATE | — | Overweight |
| May 15, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| May 15, 2026 | Wedbush | UPGRADE | Neutral | Outperform |
| May 15, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 30, 2026 | Mizuho | INITIATE | — | Outperform |
| Apr 23, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 17, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 7, 2026 | Leerink Partners | INITIATE | — | Outperform |
| Mar 25, 2026 | Deutsche Bank | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
| Mar 24, 2026 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Jan 20, 2026 | Citizens | UPGRADE | Market Perform | Market Outperform |
| Dec 22, 2025 | HC Wainwright & Co. | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 13 | 1 | 1 | 0 | 90% | |
| May 1, 2026 | 4 | 11 | 2 | 1 | 0 | 83% | |
| Apr 1, 2026 | 3 | 10 | 2 | 1 | 0 | 81% | |
| Mar 1, 2026 | 3 | 8 | 4 | 1 | 0 | 69% | |
| Feb 1, 2026 | 3 | 8 | 4 | 1 | 0 | 69% | |
| Jan 1, 2026 | 3 | 7 | 5 | 1 | 0 | 63% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 14, 2026
earnings
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
<p align="center"><em>– On track to report initial safety, PK and early activity from</em> <em>Phase 1 dose-escalation trial of STRO-004, potential be
May 6, 2026
earnings_calendar
STRO Q1 2026 Earnings Scheduled — 2026-05-06
Apr 19, 2026
fda
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
<p align="center"><em>STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing </em><em>solid tumor PDX models, wi
Apr 6, 2026
Clinical Trial
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Phase Phase 2 — COMPLETED
Mar 23, 2026
earnings
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
<p align="center"><em>– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial c
Mar 11, 2026
earnings_calendar
STRO Q4 2025 Earnings After Market Close — 2026-03-11